We are live on ! Find out more
LLY icon

Eli Lilly

1,673 hedge funds and large institutions have $98.1B invested in Eli Lilly in 2019 Q4 according to their latest regulatory filings, with 241 funds opening new positions, 521 increasing their positions, 585 reducing their positions, and 66 closing their positions.

New
Increased
Maintained
Reduced
Closed

265% more first-time investments, than exits

New positions opened: 241 | Existing positions closed: 66

90% more funds holding in top 10

Funds holding in top 10: 2038 (+18)

18% more capital invested

Capital invested by funds: $83.2B → $98.1B (+$14.9B)

10% more funds holding

Funds holding: 1,5251,673 (+148)

0.56% more ownership

Funds ownership: 77.13%77.7% (+0.56%)

11% less repeat investments, than reductions

Existing positions increased: 521 | Existing positions reduced: 585

19% less call options, than puts

Call options by funds: $605M | Put options by funds: $751M

Holders
1,673
Holders Change
+148
Holders Change %
+9.7%
% of All Funds
32.96%
Holding in Top 10
38
Holding in Top 10 Change
+18
Holding in Top 10 Change %
+90%
% of All Funds
0.75%
New
241
Increased
521
Reduced
585
Closed
66
Calls
$605M
Puts
$751M
Net Calls
-$146M
Net Calls Change
-$120M
Name Holding Trade Value Shares
Change
Change in
Stake
VRS
126
Virginia Retirement Systems
Virginia
$50.2M -$46.4K -400 -0.1%
NIPH
127
NN Investment Partners Holdings
Netherlands
$50.2M +$3.58M +30,888 +9%
Nisa Investment Advisors
128
Nisa Investment Advisors
Missouri
$49.3M -$415K -3,581 -0.9%
CII
129
Capital International Inc
California
$48.7M -$1.41M -12,192 -3%
PFC
130
Poplar Forest Capital
California
$47.3M -$10.9M -94,136 -21%
Stifel Financial
131
Stifel Financial
Missouri
$46.7M +$3.46M +29,864 +9%
DekaBank Deutsche Girozentrale
132
DekaBank Deutsche Girozentrale
Germany
$46.6M -$30.6M -263,844 -43%
BFC
133
Bedel Financial Consulting
Indiana
$46.6M -$286K -2,468 -0.7%
H
134
Hexavest
Quebec, Canada
$46.6M +$12.2M +105,065 +42%
Canada Pension Plan Investment Board
135
Canada Pension Plan Investment Board
Ontario, Canada
$46.6M -$27M -232,729 -40%
NC
136
Nicholas Company
Wisconsin
$45.8M +$6.25M +53,950 +18%
HighTower Advisors
137
HighTower Advisors
Illinois
$45.4M +$2.29M +19,752 +6%
KBC Group
138
KBC Group
Belgium
$44.9M -$10.1M -86,989 -20%
PR
139
Payden & Rygel
California
$44.9M +$7.74M +66,800 +24%
ACI
140
AMP Capital Investors
Australia
$44.1M -$10M -86,281 -20%
PCA
141
Private Capital Advisors
Connecticut
$44.1M
William Blair & Company
142
William Blair & Company
Illinois
$44.1M +$5.82M +50,249 +18%
Russell Investments Group
143
Russell Investments Group
United Kingdom
$43.8M +$1.19M +10,264 +3%
CWM
144
CIBC World Markets
New York
$43.4M -$2.3M -19,809 -6%
Federated Hermes
145
Federated Hermes
Pennsylvania
$43.3M +$10.9M +93,730 +40%
JMPWA
146
JP Morgan Private Wealth Advisors
California
$42.6M +$217K +1,875 +0.6%
WAM
147
Weatherly Asset Management
California
$42.4M +$19.7K +170 +0.1%
Aviva
148
Aviva
United Kingdom
$41.1M -$1.6M -13,813 -4%
GIM
149
Goelzer Investment Management
Indiana
$40.8M -$104K -900 -0.3%
APG Asset Management
150
APG Asset Management
Netherlands
$40.6M -$35.4M -305,401 -47%

LLY Hedge Fund Activity: Q4 2019 in Review

1,673 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q4 2019, worth a combined $98.1B — up 18% from $83.2B a quarter earlier.

Buyers outnumbered sellers: 241 funds opened new LLY positions and 66 closed out — a net gain of 175 holders — while 521 added to existing stakes and 585 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $543M. The largest seller was Nuveen, cutting an estimated $318M.

  • 1,673 institutional investors held Eli Lilly (LLY) as of Q4 2019, up from 1,525 in Q3 2019.
  • Funds reported $98.1B of Eli Lilly stock for Q4 2019, up 18% quarter-over-quarter.
  • 241 funds opened new Eli Lilly positions in Q4 2019 and 66 closed out, a net change of +175 holders.
  • The largest Eli Lilly buyer in Q4 2019 was Wellington Management Group, an estimated $543M added.
  • The largest Eli Lilly seller in Q4 2019 was Nuveen, an estimated $318M sold.

Based on aggregated 13F filings for Q4 2019.